Top-News

Inovio Pharmaceuticals Aktie News

Aktie
WKN:  A400EJ ISIN:  US45773H4092 US-Symbol:  INO Branche:  Biotechnologie Land:  USA
2,00 $
-0,02 $
-0,99%
1,7170 € 16:32:03 Uhr
Depot/Watchlist
Marktkapitalisierung *
63,84 Mio. €
Streubesitz
78,72%
KGV
-0,46
Index-Zuordnung
-

Inovio Pharmaceuticals News

18.11.25 - PR Newswire
INOVIO to Participate in December Investor Conferences
INOVIO to Participate in December Investor Conferences PR Newswire
11.11.25 - PR Newswire
INOVIO Announces Pricing of $25 Million Public Offering
INOVIO Announces Pricing of $25 Million Public Offering PR Newswire
10.11.25 - PR Newswire
INOVIO Announces Proposed Public Offering
INOVIO Announces Proposed Public Offering PR Newswire
10.11.25 - PR Newswire
INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights
INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights PR Newswire
03.11.25 - PR Newswire
INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults
INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults PR Newswire
31.10.25 - PR Newswire
INOVIO Reports Inducement Grant Under Inducement Plan
INOVIO Reports Inducement Grant Under Inducement Plan PR Newswire
27.10.25 - PR Newswire
INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025
INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025 PR Newswire
23.10.25 - PR Newswire
INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference
INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference PR Newswire
21.10.25 - PR Newswire
Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine
Clinical Proof-​of-Concept Data for DNA-​Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine PR Newswire
02.10.25 - PR Newswire
INOVIO Reports Inducement Grant Under Inducement Plan
INOVIO Reports Inducement Grant Under Inducement Plan PR Newswire
25.09.25 - PR Newswire
INOVIO to Participate in Upcoming Scientific Conferences
INOVIO to Participate in Upcoming Scientific Conferences PR Newswire
26.08.25 - PR Newswire
INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults
INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults PR Newswire
25.08.25 - PR Newswire
INOVIO to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
INOVIO to Participate in the H.C. Wainwright 27th Annual Global Investment Conference PR Newswire
14.08.25 - PR Newswire
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment PR Newswire
12.08.25 - PR Newswire
INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights
INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights PR Newswire
11.08.25 - PR Newswire
Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)
Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP) PR Newswire
04.08.25 - PR Newswire
INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025
INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025 PR Newswire
07.07.25 - PR Newswire
INOVIO to Present at Upcoming Scientific Conference
INOVIO to Present at Upcoming Scientific Conference PR Newswire
03.07.25 - PR Newswire
INOVIO Announces Pricing of $25 Million Public Offering
INOVIO Announces Pricing of $25 Million Public Offering PR Newswire
02.07.25 - PR Newswire
INOVIO Announces Proposed Public Offering
INOVIO Announces Proposed Public Offering PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +2,17%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »